RETATRUTIDE 40 mg
Professional Pharmaceutical Product Description

Important note: Retatrutide is the generic/investigational name of Lilly’s molecule LY3437943. It is not currently approved and is legally available only through authorized Lilly clinical trials, so the content below should be used as a medical-reference style summary, not as approved prescribing or promotional copy. Current public Lilly materials describe retatrutide as being in Phase 3 development.

Product Name & Packaging

Brand/Reference Name: Retatrutide
Generic Name: Retatrutide
Development Code: LY3437943
Strength & Packaging: 40 mg
Dosage Form: Subcutaneous injection

Retatrutide 30 mg should be treated as an investigational reference strength. Because retatrutide is still in development, there is no standardized approved commercial packaging or public marketed product label for routine pharmacy distribution. Public Lilly materials have described Phase 2 regimens up to 12 mg and Phase 3 programs with maintenance doses including 4 mg, 9 mg, and 12 mg; a 30 mg presentation should therefore be verified against the specific study protocol or supplier documentation before publication.

Description

Retatrutide is an investigational, once-weekly injectable triple receptor agonist designed to activate the GIP, GLP-1, and glucagon receptors. It is being studied for metabolic and weight-related conditions in ongoing clinical development.

Indications

Retatrutide currently has no approved indications. According to Lilly, it is being studied in Phase 3 programs for obesity, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

Dosage & Administration

There is no approved dosage and administration schedule for commercial clinical use. In Lilly’s public materials, retatrutide has been administered as a once-weekly subcutaneous injection using dose-escalation regimens. Published and announced study programs have evaluated regimens including 1 mg, 4 mg, 8 mg, and 12 mg in Phase 2 obesity research, and 4 mg, 9 mg, and 12 mg in later Phase 3 reporting. For a 30 mg presentation, the exact dosing schedule and package configuration should therefore be confirmed against the specific investigational source rather than assumed from an approved label.

Mechanism of Action

Retatrutide acts as an agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucagon receptor. Lilly Medical states that this multimodal activity is being studied for effects on food intake, energy expenditure, lipid metabolism, glucose homeostasis, insulin secretion, and inflammation.

Precautions

Because retatrutide remains investigational, its full regulatory safety labeling has not been established. Available Lilly information supports caution regarding gastrointestinal intolerance during dose escalation, and Lilly specifically warns that products claiming to be retatrutide outside Lilly-sponsored studies may be fake or unsafe.

Side Effects

Across Lilly’s public trial materials, the most commonly reported adverse events have been gastrointestinal, especially nausea, diarrhea, and vomiting. These effects were reported primarily during the dose-escalation period; some reports also note constipation, decreased appetite, and dysesthesia in certain study populations.

Storage

Because retatrutide is not an approved marketed medicine, there is no publicly available approved commercial storage label for standard pharmacy catalog use. Storage and handling should follow the specific investigational protocol, sponsor instructions, and applicable regulatory requirements for the supplied material.